1. Treatment of Stage III Non-small Cell Lung Cancer
Nithya Ramnath, MD, Thomas J. Dilling, MD, Loren J. Harris, MD, FCCP, Anthony W. Kim, MD, FCCP, Gaetane C. Michaud, MD, FCCP, Alex A. Balekian, MD, MSHS, Rebecca Diekemper, MPH, Frank C. Detterbeck, MD, FCCP, Douglas A. Arenberg, MD, FCCP 
CHEST 
Volume 143, Issue 5, Pages e314S-e340S (May 2013)
DOI: /chest
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

2. Figure 1
[Section 2.1] Addition of cisplatin-based chemotherapy to radiotherapy improves survival in stage III NSCLC.
CHEST  , e314S-e340SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

3. Figure 2
[Section 2.2, 3.3] A depiction of the heterogeneous patient characteristics of stage III lung cancer and the inclusion of various patient subtypes into clinical studies evaluating treatment options for patients with stage III disease. PS = performance status; RT = radiotherapy.
CHEST  , e314S-e340SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

4. Figure 3
[Section 2.2] Concurrent vs sequential chemoradiotherapy treatment details.
CHEST  , e314S-e340SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

5. Figure 4
[Section 3.1] Randomized phase 3 trials of preoperative therapy followed by surgery vs surgery alone for stage III NSCLC.
CHEST  , e314S-e340SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

6. Figure 5
[Section 3.2] Outcomes of preoperatively identified N2 involvement with primary surgery.
CHEST  , e314S-e340SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

7. Figure 6
[Section 3.3] Randomized phase 3 trials of preoperative therapy followed by surgery vs chemoradiotherapy for stage III NSCLC.
CHEST  , e314S-e340SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

8. Figure 7
[Section 3.3] Survival of patients with stage IIIA (N2) lung cancer treated with CT/RT or CT/RT/S from the North American Intergroup Study A, Progression-free survival. B, Overall survival. The initial steeper slope of the trimodality arm demonstrates the importance of the perioperative mortality rate on the overall results of trimodality therapy. CT/RT = chemotherapy and radiotherapy; CT/RT/S = chemotherapy and radiotherapy followed by surgery.
CHEST  , e314S-e340SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

9. Figure 8
[Section 3.3.1] Selection criteria for trimodality therapy with surgery in patients with stage III (N2) lung cancer.
CHEST  , e314S-e340SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

10. Figure 9
[Section 3.3.2] Outcomes of patients with persistent N2 after induction therapy (ypN2) who underwent resection.
CHEST  , e314S-e340SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

11. Figure 10
[Section 3.3.2] Survival of patients having surgery after poor response to induction therapy.
CHEST  , e314S-e340SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

12. Figure 11 [Section 4.1] MLND: survival and recurrence data.
CHEST  , e314S-e340SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

13. Figure 12
[Section 4.2] NSCLC adjuvant studies that included patients with stage III disease: survival with adjuvant chemotherapy.
CHEST  , e314S-e340SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions